Associate Director, Clinical Assay Strategy, Flu
CSL Behring, Waltham, MA, Hybrid
Clinical ResearchBachelor RequiredExecutive Director
CSL Behring, Waltham, MA, Hybrid
CSL Seqirus is a global leader in influenza prevention and the world’s second-largest influenza vaccine provider, operating as a specialized division of CSL Limited. Headquartered in Melbourne, Australia, with major manufacturing hubs in Holly Springs, NC, and Liverpool, UK, the company operates the world’s largest cell-based vaccine facility and serves as a primary partner to governments for global pandemic preparedness. Joining Seqirus now means being part of an agile team committed to developing vaccines that make a meaningful difference worldwide.
Could you be our next Associate Director, Clinical Assay Strategy-Flu? The job is in our Waltham, MA Office. This is a hybrid position and is onsite three days a week. You will report to the Director, Clinical Assay Strategy.
This role is intended for a recognized subject matter expert who understands the scientific, operational, and regulatory evolution of influenza immunogenicity assessment, including HAI, microneutralization (MN), ELLA, and multiplex platforms, and can strategically navigate assay modernization while maintaining regulatory alignment.
You will provide scientific leadership and external oversight of vaccine serology and biomarker assays supporting clinical development programs. This is a strategic, non-laboratory-based role responsible for assay design, validation oversight, regulatory alignment, and vendor governance across global clinical programs.
The expected base salary range for this position at hiring is $179,000 - $212,000. Please note this salary range reflects the minimum and maximum base pay that CSL expects to pay for this position at the time of this posting. Individual base salary for a successful candidate is determined by qualifications, skill level, experience, competencies and other relevant factors. In addition to base salary, total compensation for this role may also include incentive compensation and equity.
CSL Seqirus is part of CSL. As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
To learn more about CSL, CSL Behring, CSL Seqirus and CSL Vifor visit
CSL Behring is a global biotherapeutics leader specializing in biologics for rare and serious diseases, leveraging over a century of expertise.
View company profile →